Enabling Access When It Matters Most
What happens when specialised or emergency medicines are not available to the South African market?
When essential registered medicines are unavailable, in short supply or insufficient to meet clinical need, Lamar International (Pty) Ltd enables rapid access through the Section 21 regulatory pathway which is governed by the South African Medicines and Related Substances Act 101 (of 1965). Lamar helps source and procure essential medicines, navigating complex supply chains efficiently and responsibly, in alignment with South African regulatory pathways.
We work closely with clinicians, hospitals, and SAHPRA to facilitate the responsible and compliant importation and supply of unregistered medicines – subject to applicable approvals and requirements – ensuring patients receive timely treatment when standard supply channels are disrupted or when special medicines are not yet available to the South African market.
Rapid Response for Hospitals and Healthcare Providers
We assist hospitals and healthcare professionals in accessing emergency medicines at short notice, ensuring:
- Fast turnaround times for urgent supply requests
- Responsive coordination across international supply chains
- Reliable access pathways during critical shortages
- Only quality medicines procured from GMP-certified facilities to which SAHPRA aligns.
Our operational model is built to support time-sensitive clinical needs without compromising compliance or quality.
Section 21 Procurement Expertise
Lamar offers extensive expertise in Section 21 procurement, supporting both Named Patient and Bulk hospital requirements:
- Application support aligned to SAHPRA requirements
- Efficient handling of Authorisation processes
- NAPPI code applications following Authorisation approval:
- For Named Patient use
- For bulk orders to facilitate medical aid claims.
This ensures not only access, but also reimbursement readiness and administrative continuity for healthcare providers.
We prioritise sustainable access to high-quality medicines through a rigorously governed supply model:
- GMP-certified manufacturing sites and partners
- Products sourced from GMP-compliant facilities:
- European Union (EU)
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S)
- All other regulatory bodies to which SAHPRA aligns.
- SAHPRA-aligned procurement and importation processes
Certain bulk hospital lines are readily available and warehoused in a SAHPRA-approved facility, enabling faster deployment when needed.
Governance & Quality Assurance Framework
Our supply ecosystem is underpinned by strict quality and compliance principles:
- Documented quality oversight across all supply partners
- Robust vendor qualification processes
- End-to-end traceability systems
- A proactive supply continuity mindset
All products are manufactured under strict GMP standards through vetted partners. We prioritise quality assurance, supplier governance, and documentation integrity to support consistent, compliant supply.
Trusted Partner in Critical Access
Lamar International (Pty) Ltd combines regulatory expertise, operational agility, and quality assurance to support healthcare systems when access to essential medicines is most critical – responsibly, compliantly, and without compromise.
Why Choose Lamar?
- Proven expertise navigating Section 21 processes.
- Established global sourcing network ensuring only accredited vendors.
- Strong relationships with hospitals and clinicians.
- Ability to ensure access to consistent supply.
- Procurement of quality medicines.
For more information on/requests for Section 21, kindly complete the form below or email: section21@lamar.co.za